Overview

* Belite Bio ( BLTE ) reports Q3 net loss of $21.7 mln, increased from $8.7 mln last year

* Company completed $15 mln direct offering and $125 mln private placement

* China's NMPA and UK's MHRA accept Tinlarebant applications based on DRAGON trial

Outlook

* Company expects final DRAGON trial data in Q4 2025

* Company anticipates interim analysis for PHOENIX trial

* Company aims for regulatory milestones with Tinlarebant

Result Drivers

* INCREASED R&D EXPENSES - Driven by costs associated with DRAGON and PHOENIX trials, partially offset by Australian R&D tax incentive

* FINANCIAL STRENGTHENING - Completion of $15 mln direct offering and $125 mln private placement enhances financial position

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$21.69

Income mln

Q3 -$23.02

Income mln

From

Operatio

ns

Q3 $23.02

Operatin mln

g

Expenses

Q3 -$21.69

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Belite Bio Inc ( BLTE ) is $104.00, about 8.8% below its November 7 closing price of $113.19

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)